Patents Examined by Christian L. Fronda
  • Patent number: 11618891
    Abstract: This disclosure relates to thermophilic family B DNA polymerases comprising a neutral amino acid residue at a certain position near the C-terminus of the catalytic domain, which corresponds to a position occupied by a basic amino acid residue in wild-type Pfu polymerase. The thermophilic family B DNA polymerases provided herein also comprise an N-terminal domain comprising a uracil-binding pocket that has been modified to reduce template uracil binding. Related uses, methods, and compositions are also provided. In some embodiments, the polymerases comprise a 3?-5? exonuclease domain and/or a sequence non-specific dsDNA binding domain.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: April 4, 2023
    Assignee: Thermo Fisher Scientific Baltics UAB
    Inventors: Rasa Sukackaite, Skaiste Valinskyte
  • Patent number: 11613769
    Abstract: Microbial cell lines suitable for industrial-scale production of organic acids and methods of making and isolating such cell lines.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: March 28, 2023
    Assignee: S&P Ingredient Development, LLC
    Inventors: Paul Blum, Sambasiva Rao Chigurupati, Derrick Jermaine White
  • Patent number: 11612619
    Abstract: Compositions, methods, and systems for modifying sterol metabolism in a subject is disclosed. In some embodiments, the subjects may be administered one or more mammalian cells modified to express at least one sterol degrading enzyme derived from a bacterium. In many embodiments, the cell is a macrophage or monocyte stably expressing three or more enzymes that aid in opening the ? ring of cholesterol. The disclosed compositions and methods may be useful in lowering cholesterol levels in a subject in need thereof. In some embodiments, the subject may have a genetic predisposition to atherosclerosis.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: March 28, 2023
    Assignee: National Institute of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
    Inventors: Richard Eric Honkanen, Brandon Marshall D'Arcy, Mark Raymond Swingle
  • Patent number: 11603545
    Abstract: The present invention discloses an engineering yeast strain for producing nervonic acids. The yeast strain over-expresses the genes related to enzymes required in a synthetic process of long-chain unsaturated fatty acids, such as fatty acid elongase, desaturase, diacylglycerol acyltransferase and the like, and optionally, further adjusts and controls the synthesis and decomposition route of triglyceride, the synthesis and decomposition route of sphingomyelin, and the synthesis and decomposition route and the oxidation-reduction balanced route of lipid subcell levels. The recombinant yeast strain can produce microorganism oil; and the content of the prepared nervonic acids accounts for 39.6% of the total fatty acids.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: March 14, 2023
    Assignees: ZHEJIANG ZHENYUAN BIOTECH CO. LTD., QINDAO INSTITUTE OF BIOENERGY AND BIOPROCESS TECHNOLOGY, CHINESE ACADEMY OF SCIENCES
    Inventors: Fuli Li, Shian Wang, Weiming Fan, Huimin Meng, Kai Zhang, Jiaxin Li
  • Patent number: 11603521
    Abstract: Provided is an amino acid dehydrogenase mutant. The amino acid sequence of the mutant is obtained by mutating the amino acid sequence shown in SEQ ID NO:1. The mutation includes at least one of the following mutation sites: 64th, 94th, 133rd, 137th, 148th, 168th, 173rd, 183 rd, 191st, 207th, 229th, 248th, 255th and 282nd sites; or the amino acid sequence of the amino acid dehydrogenase mutant is an amino acid sequence having the mutation sites in the mutated amino acid sequence and having a 80% or more homology with the mutated amino acid sequence. The mutant enzyme activity is more than 50 times higher than that of wild amino acid dehydrogenase, and the enzyme specificity is also correspondingly improved.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: March 14, 2023
    Assignee: ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD
    Inventors: Hao Hong, Gage James, Jiangping Lu, Na Zhang, Xuecheng Jiao, Rui Li, Kejian Zhang, Yu Zhang, Yiming Yang
  • Patent number: 11597740
    Abstract: The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: March 7, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Patent number: 11591584
    Abstract: The invention provides a composition comprising a proteinase or an enzymatically active fragment thereof, said proteinase comprising the amino acid sequence of SEQ ID NO: 1 or comprising an amino acid sequence which is at least about 70% identical to SEQ ID NO: 1, wherein i) the concentration of free calcium in said composition is ?about 80 ?M; or ii) the concentration of monovalent salt in said composition is ?about 20 mM. Under such conditions, the proteinases and enzymatically active fragments thereof are inducibly thermolabile. The invention further provides samples comprising one or more polypeptides and a proteinase or an enzymatically active fragment thereof, said proteinase comprising the amino acid sequence of SEQ ID NO: 1 or comprising an amino acid sequence which is at least about 70% identical to SEQ ID NO: 1, wherein i) the concentration of free calcium in said sample is ?about 80 ?M; or ii) the concentration of monovalent salt in said sample is ?about 20 mM.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: February 28, 2023
    Assignee: ARCTICZYMES AS
    Inventors: Bernd Ketelsen Striberny, Cathrine Pedersen, Jørn Remi Henriksen, Olav Lanes, Marit Sjo Lorentzen
  • Patent number: 11591627
    Abstract: The disclosure relates, in some aspects, to compositions and methods useful for production of nitrated aromatic molecules. The disclosure is based, in part, on whole cell systems expressing artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes. In some aspects, the disclosure relates to methods of producing nitrated aromatic molecules in whole cell systems having artificial fusion proteins comprising cytochrome P450 enzymes linked to reductase enzymes.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: February 28, 2023
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Yousong Ding, Ran Zuo
  • Patent number: 11582994
    Abstract: Disclosed is a method for the manufacture of a spray-dried powder consisting essentially of 3-fucosyllactose, the spray-dried powder, its use for the manufacture of nutritional compositions, and nutritional compositions containing the spray-dried powder.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: February 21, 2023
    Assignee: Chr. Hansen HMO GmbH
    Inventor: Stefan Jennewein
  • Patent number: 11584914
    Abstract: A process for culturing Clostridium saccharoperbutylacetonicum cells, which are capable of growing on gamma-cyclodextrin in a liquid culture medium in a culture vessel. Also disclosed is a process for producing a bio-product, the process comprising culturing Clostridium saccharoperbutylacetonicum cells, which are capable of growing on gamma-cyclodextrin in a liquid culture medium in a culture vessel.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: February 21, 2023
    Assignee: Biocleave Limited
    Inventors: Elizabeth Jenkinson, Amanda J. Nicolle, Aretha N. Atmadjaja
  • Patent number: 11576400
    Abstract: Methods and systems for producing improved hemp seed products, such as proteins and oils are provided.
    Type: Grant
    Filed: August 11, 2021
    Date of Patent: February 14, 2023
    Assignee: Victory Foods, PBC
    Inventors: Chad Wakeland-Rosen, Benjamin Raymond
  • Patent number: 11578316
    Abstract: Compositions and methods are provided comprising acetolactate decarboxylase (ALDC) enzyme variants having higher specific activity. Composition and method are provided where the ALDC variants are used in combination with metal ions to further increase stability and/or activity.
    Type: Grant
    Filed: September 12, 2017
    Date of Patent: February 14, 2023
    Assignee: DUPONT NUTRITION BIOSCIENCES APS
    Inventors: Jacob Flyvholm Cramer, Lene Kragh
  • Patent number: 11566266
    Abstract: The present invention relates to processes for producing fermentation products from starch-containing material, wherein a thermostable alpha-amylase and optionally a thermostable protease are present and/or added during liquefaction. The invention also relates to a composition suitable for use in a process of the invention.
    Type: Grant
    Filed: September 29, 2020
    Date of Patent: January 31, 2023
    Assignee: NOVOZYMES A/S
    Inventors: Randy Deinhammer, Suzanne Clark, Mauricio Quiros, John Matthews, Anne Glud Hjulmand, Chee Leong Soong, Tomoko Matsui, Shinobu Takagi
  • Patent number: 11555212
    Abstract: The present invention generally relates to the field of biotechnology as it applies to the production of aryl sulfates using recombinant host cells. More particularly, the present invention pertains to recombinant host cells comprising (e.g., expressing) a polypeptide having aryl sulfotransferase activity, wherein said recombinant host cells have been modified to have an increased uptake of sulfate compared to identical host cells that does not carry said modification. Further provided are processes for the production of aryl sulfates, such as zosteric acid, employing such recombinant host cells.
    Type: Grant
    Filed: January 27, 2021
    Date of Patent: January 17, 2023
    Assignee: CysBio ApS
    Inventors: Christian Bille Jendresen, Alex Toftgaard Nielsen
  • Patent number: 11549128
    Abstract: A pretreatment method for producing a raw material of lycopene, comprising: uniformly mixing tomato peel residue with a fermenting agent, an antioxidant and an enzyme preparation, and subjecting the resultant to light-proof anaerobic fermentation. The present invention employs bacteria-enzyme-combined fermentation technology, which prolongs the storage period of wet tomato peel residue, and also destroys the cell wall of tomato peels, thus facilitating exaction of lycopene and improving the purity of lycopene extracted in the later stage.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: January 10, 2023
    Assignee: CHENGUANG BIOTECH GROUP CO., LTD.
    Inventors: Qingguo Lu, Wenjie Han, Zhiming Zhang, Xiaodong An, Wei Gao, Qianli Li
  • Patent number: 11542300
    Abstract: The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of plasmaproteins, such as Factor VIII, von Willebrand factor and Factor IX. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: January 3, 2023
    Assignee: Cytiva BioProcess R&D AB
    Inventors: Martin Hall, Karolina Busson, Jean-Luc Maloisel, Helena Skoglar
  • Patent number: 11542511
    Abstract: The present invention relates to a recombinant microorganism which is capable of simultaneously fermenting at least two sugars in a lignocellulosic saccharified liquid, and also capable of generating diol.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: January 3, 2023
    Assignee: GS CALTEX CORPORATION
    Inventors: Jong-Myoung Park, Chelladurai Rathnasingh, Hyo-Hak Song
  • Patent number: 11542512
    Abstract: The present disclosure provides genetically modified host cells that produce a cannabinoid, a cannabinoid derivative, a cannabinoid precursor, or a cannabinoid precursor derivative. The present disclosure provides methods of synthesizing a cannabinoid, a cannabinoid derivative, a cannabinoid precursor, or a cannabinoid precursor derivative.
    Type: Grant
    Filed: March 19, 2021
    Date of Patent: January 3, 2023
    Assignee: The Regents of the University of California
    Inventors: Jay D. Keasling, Leo D'Espaux, Jeff Wong, Xiaozhou Luo, Michael Reiter, Charles Denby, Anna Lechner
  • Patent number: 11535875
    Abstract: Disclosed herein are host cells expressing a polypeptide, wherein the polypeptide hydrolyzes an ester linkage of a triacylglycerol in an oil comprising at least one long-chain polyunsaturated fatty acid, methods for using such host cells, and processes for production of a lipase using such host cells.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: December 27, 2022
    Assignee: DSM IP ASSETS B.V.
    Inventors: Paul Mugford, Monika Mueller, Martin Schurmann
  • Patent number: 11530415
    Abstract: The present disclosure includes refactored thaxtomin biosynthetic gene clusters including thaxtomin modules including one or more thaxtomin genes such that the expression of the refactored thaxtomin biosynthetic gene cluster produces at least one thaxtomin compound in the absence of thaxtomin-inducing conditions. Also included are genetically engineered Streptomyces bacterium from a non-pathogenic Streptomyces strain comprising an exogenous, refactored thaxtomin biosynthetic gene cluster of the present disclosure, such that the expression of the refactored thaxtomin biosynthetic gene cluster provides the genetically engineered Streptomyces bacterium with the ability to produce at least one thaxtomin compound in the absence of thaxtomin-inducing conditions. The present disclosure also includes methods of producing thaxtomin compounds, analogs, or intermediate with the refactored thaxtomin biosynthetic gene clusters and genetically engineered bacteria of the present disclosure.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: December 20, 2022
    Assignee: University of Florida Research Foundation, Incorporated
    Inventors: Yousong Ding, Guangde Jiang